Anti-Vascular-Endothelial-Growth-Factor (anti-VEGF) for the treatment of diabetic macular edema
Zechmeister I, Huic M
Record ID 32011001047
English, German
Authors' recommendations:
For some patients with DME, VEGF-inhibitors seem to be a more effective short-term treatment than alternative therapies. Evidence is not of sufficient quality to confirm safety. A decision on financing should take into account the high price-difference between the products and the fact that many studies are still ongoing.
Details
Project Status:
Completed
URL for project:
http://eprints.hta.lbg.ac.at/917
Year Published:
2011
URL for published report:
http://eprints.hta.lbg.ac.at/916
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Macular Edema
- Vascular Endothelial Growth Factors
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.